Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma - Concepedia

Concepedia

Publication | Open Access

Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

DOI Full Paper Access

13

Citations

15

References

2024

Year

Francine M. Foss, Youn H. Kim, H. Miles Prince, Oleg E. Akilov, Christiane Querfeld, Lucia Seminario‐Vidal, David C. Fisher, Timothy M. Kuzel, Costas K. Yannakou, Larisa J. Geskin,

Journal of Clinical Oncology

Abstract

Efficacy and safety results show that DD-cxdl would potentially fulfill a serious, unmet medical need for patients with R/R CTCL.

References

	Year	Citations

Page 1